Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission

Alenius, Malin; Hammarlund‐Udenaes, Margareta; Hartvig, Per; Sundquist, Staffan; Lindström, Leif

doi:10.1016/j.comppsych.2008.11.001

Cited by 6 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supportive evidence for use of LATs in younger patients in early disease, and is consistent with a retrospective review of medical records of adult patients with newly diagnosed schizophrenia which found improvements in functional remission in young patients (mean age: 24.1 years) receiving treatment with PP1M for ⩾12 months in a naturalistic clinical setting. 41 In the present analysis, somewhat higher proportions of younger than older patients and shorter than longer disease duration achieved both symptomatic and functional remission (although CIs overlapped, indicating a non-significant trend). This is in line with an observational study of a cohort of young patients with schizophrenia (<35 years) treated with LATs, which found that clinical remission correlated strongly with functional remission.…”

Section: Discussioncontrasting

confidence: 58%

“…It is associated with real-world outcomes, such as ability to work and live independently. 38 – 41 The functional remission data in this analysis indicated that younger patients had higher baseline functioning, and this was maintained to LOCF endpoint. This is supportive evidence for use of LATs in younger patients in early disease, and is consistent with a retrospective review of medical records of adult patients with newly diagnosed schizophrenia which found improvements in functional remission in young patients (mean age: 24.1 years) receiving treatment with PP1M for ⩾12 months in a naturalistic clinical setting.…”

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Pungor

Bozikas

Emsley

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis of the 52-week, phase 3b REMISSIO study analysed outcomes according to patient age and disease duration in a naturalistic clinical setting. Methods: Outcomes of patients with schizophrenia were analysed according to age [<35 years ( n = 123) versus ⩾35 years ( n = 182)] and disease duration [⩽3 years ( n = 72) versus >3 years ( n = 233)]. The primary efficacy outcome was the proportion of patients achieving symptomatic remission according to the Andreasen criteria. Adverse events were monitored throughout the study. Results: At endpoint (last observation carried forward), 60.7% (95% CI: 51.4%, 69.4%) of younger patients and 54.1% of older patients (95% CI: 46.6%, 61.6%) achieved symptomatic remission. The proportions for patients with disease duration ⩽3 years and >3 years were similar: 57.8% (45.4%, 69.4%) versus 56.5% (49.8%, 62.9%). Functional remission was reached by 45.4% (36.2%, 54.8%) of patients aged <35 years and 36% (28.9%, 43.6%) of patients aged ⩾35 years with a similar pattern when analysed by disease duration. PP3M had a favourable safety profile and was generally well tolerated in both age groups. Conclusion: Patients with schizophrenia, previously stabilized on PP1M, may benefit from PP3M treatment with some additional potential improvements if started early in the disease course. Clinical trials.gov: NCT02713282

show abstract

Section: Discussioncontrasting

confidence: 58%

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Pungor

Bozikas

Emsley

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…9–11 However, it can be argued that functional remission might be an even more important objective, as it is associated with real-world outcomes such as being able to work and live independently. 12–14…”

Section: Introductionmentioning

confidence: 99%

“…[9][10][11] However, it can be argued that functional remission might be an even more important objective, as it is associated with realworld outcomes such as being able to work and live independently. [12][13][14] Suboptimal adherence to daily oral antipsychotic medication is common in people with schizophrenia and is associated with poorer outcomes, [15][16][17][18] including an increased risk of relapse or hospitalization. 19,20 In light of this, long-acting injectable antipsychotic treatments (LATs) were developed to overcome the need for people with schizophrenia to take daily oral antipsychotic medication.…”

Section: Introductionmentioning

confidence: 99%

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

García-Portilla

Llorca²,

Maina

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated the efficacy and safety of converting patients with schizophrenia stabilized with paliperidone palmitate 1-month (PP1M) to PP3M in a naturalistic clinical setting. Methods: After screening (days –7 to 1), patients were converted from PP1M (50–150 mg eq.) to PP3M (175–525 mg eq.), and entered a 52-week, flexible-dose PP3M treatment period. The primary efficacy endpoint was symptomatic remission (SR) (Andreasen criteria) at last observation carried forward (LOCF) endpoint. Results: Patients ( n = 305) received PP3M, of whom 291 (95.4%) completed the study. Doses of PP3M remained stable during the 12-month treatment period, and changes in dose were uncommon. Overall, 56.8% of patients [95% confidence interval (CI): 51.0, 62.4] achieved SR, and 31.8% achieved both symptomatic and functional remission (Personal and Social Performance scale total score > 70) at LOCF endpoint. Secondary endpoint results were generally consistent with primary endpoint results. There were improvements in Positive and Negative Syndrome Scale total, subscale and Marder factor scores, and also Clinical Global Impression-Severity and -Change scores from baseline to LOCF endpoint. Carer burden was reduced, and the proportion of patients requiring hospitalization for psychiatric reasons decreased from 13.5% in the 12 months prior to baseline to 4.6% during the treatment period. No new safety signals were identified. Conclusion: Results from this naturalistic study were similar to those observed in previous randomized clinical trials of PP3M and underline the importance of continuous maintenance treatment in patients with schizophrenia.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission

Cited by 6 publications

References 53 publications

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About